Table 3 Univariate analysis for... | American Society of Hematology

Table 3

Univariate analysis for neutrophil recovery, relapse and disease-free survival

Risk factor	n	Neutrophil recovery			Relapse			DFS
Risk factor	n	No. of events	CI at day 60, %	P	No. of events	CI at 5 y, %	P	No. of events	Prob. at 5 y, %	P
Year of transplantation
Before 2000	70	60	84 ± 4	.07	38	54 ± 6	.07	46	34 ± 6	.01
2000 or later	77	73	95 ± 3		29	39 ± 6		34	54 ± 6
Patient sex
Female	57	52	89 ± 5	.96	22	40 ± 7	.19	26	53 ± 7	.11
Male	90	81	90 ± 3		45	51 ± 5		54	39 ± 5
Patient age
Younger than 5 y	73	71	97 ± 2	.01	36	51 ± 6	.26	39	45 ± 6	.87
5 y or older	74	62	82 ± 5		31	43 ± 6		41	43 ± 6
Disease status at RCBT
Early-intermediate	110	101	91 ± 3	.78	46	43 ± 5	.03	57	47 ± 5	.10
Advanced	37	32	86 ± 6		21	57 ± 8		23	37 ± 8
Infused TNC
Less than 4.1 × 10⁷/kg	72	62	85 ± 4	.001	34	49 ± 6	.71	44	37 ± 6	.11
4.1 × 10⁷/kg or greater	69	65	94 ± 3		30	45 ± 6		33	51 ± 6
Type of myeloablative conditioning
Busulfan-based	72	66	92 ± 3	.33	37	54 ± 6	.08	41	40 ± 6	.44
TBI-based	71	63	88 ± 4		28	39 ± 6		37	48 ± 6
Use of MTX
No	126	117	92 ± 2	.009	55	45 ± 5	.15	65	47 ± 5	.02
Yes	21	16	76 ± 10		12	57 ± 11		15	27 ± 10

Risk factor	n	Neutrophil recovery			Relapse			DFS
Risk factor	n	No. of events	CI at day 60, %	P	No. of events	CI at 5 y, %	P	No. of events	Prob. at 5 y, %	P
Year of transplantation
Before 2000	70	60	84 ± 4	.07	38	54 ± 6	.07	46	34 ± 6	.01
2000 or later	77	73	95 ± 3		29	39 ± 6		34	54 ± 6
Patient sex
Female	57	52	89 ± 5	.96	22	40 ± 7	.19	26	53 ± 7	.11
Male	90	81	90 ± 3		45	51 ± 5		54	39 ± 5
Patient age
Younger than 5 y	73	71	97 ± 2	.01	36	51 ± 6	.26	39	45 ± 6	.87
5 y or older	74	62	82 ± 5		31	43 ± 6		41	43 ± 6
Disease status at RCBT
Early-intermediate	110	101	91 ± 3	.78	46	43 ± 5	.03	57	47 ± 5	.10
Advanced	37	32	86 ± 6		21	57 ± 8		23	37 ± 8
Infused TNC
Less than 4.1 × 10⁷/kg	72	62	85 ± 4	.001	34	49 ± 6	.71	44	37 ± 6	.11
4.1 × 10⁷/kg or greater	69	65	94 ± 3		30	45 ± 6		33	51 ± 6
Type of myeloablative conditioning
Busulfan-based	72	66	92 ± 3	.33	37	54 ± 6	.08	41	40 ± 6	.44
TBI-based	71	63	88 ± 4		28	39 ± 6		37	48 ± 6
Use of MTX
No	126	117	92 ± 2	.009	55	45 ± 5	.15	65	47 ± 5	.02
Yes	21	16	76 ± 10		12	57 ± 11		15	27 ± 10

DFS indicates disease-free survival; OS, overall survival; CI, cumulative incidence; Prob, probability; RCBT, related cord blood transplantation; TNC, total nucleated cells; TBI, total body irradiation; and MTX, methotrexate.

Other factors analyzed but found to have no significant association with any of the outcomes in the whole cohort are patient's cytomegalovirus status, previous autologous transplantation, ABO matching, and sex matching.

View Large

This Feature Is Available To Subscribers Only